Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma

Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma

Abstract Background Ewing sarcoma (EWS) is an aggressive sarcoma with few treatment options for patients with relapsed disease. Cyclin‐dependent kinase 4 (CDK4) is a genomic vulnerability in EWS that is synergistic with IGF‐1R inhibition in preclinical studies. We present the results of a phase 2 st...

Full description

Bibliographic Details
Main Authors: David S. Shulman, Priscilla Merriam, Edwin Choy, Lillian M. Guenther, Kerri L. Cavanaugh, Pei‐Chi Kao, Andrew Posner, Ketki Bhushan, Grace Fairchild, Emma Barker, Kelly Klega, Kimberly Stegmaier, Brian D. Crompton, Wendy B. London, Steven G. DuBois
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:Cancer Medicine
Subjects:
CDK4/6
Ewing sarcoma
ganitumab
IGF‐1R
palbociclib
Online Access:https://doi.org/10.1002/cam4.6208

Internet

https://doi.org/10.1002/cam4.6208

Similar Items